Explore the words cloud of the Sea4Pain project. It provides you a very rough idea of what is the project "Sea4Pain" about.
The following table provides information about the project.
SEA4US BIOTECNOLOGIA E RECURSOS MARINHOS LDA
|Coordinator Country||Portugal [PT]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2018-05-01 to 2018-09-30|
Take a look of project's partnership.
|1||SEA4US BIOTECNOLOGIA E RECURSOS MARINHOS LDA||PT (SAGRES)||coordinator||50˙000.00|
'The Sea4Pain project will expand and define the development strategy for Sea4Us’s “Drug Discovery and Development Platform” – a platform that applies novel biotechnological approaches to exploit marine derived compounds for the development of novel pharmaceuticals highly relevant for biomedicine. The first lab-based research results have clearly demonstrated the benefits of marine compounds in a series of pathologies, like chronic pain, and the huge potential of its derivate products in the health market. In particular, our innovative breakthroughs will lead to the development of a unique, high efficacy analgesic (ion channel modulator), with reduced toxicity and limited side-effects (Sea4Pain). This extremely innovative approach shows a differentiated mode-of-action (acting directly in the 'pain switch'), that will give rise to a new class of pharmaceutical drugs with no expected adverse effects on the brain (currently being patented). The disruptive compound will modulate specific ion channels in pain-sensing neurons (Kv), for which there is no known modulator, and ease the suffering of one fifth of the World's population who constantly suffer from chronic pain. Sea4Pain will offer alternative treatments for patients suffering from moderate to severe chronic pain. Current drugs in the market (opioid derivatives and others) do alleviate pain but co-inflict important noxious effects (habituation, addiction, loss of drive) and great loss in quality of life. The global pain management drugs and devices market was estimated to be worth $38 billion in 2015 and reach $51 billion in 2022 at a CAGR of 4%. Founded in 2013, Sea4Us has received over 525.000€ in Portuguese and European Research Grants, raised 10.000€ with crowdfunding, and 250.000€ in venture capital, supporting a team of 13 professionals and is focused on developing the Sea4Pain roll-to-market of innovative treatments.'
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SEA4PAIN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SEA4PAIN" are provided by the European Opendata Portal: CORDIS opendata.
Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any contRead More
IOT and cloud computing for online medical analysis service platformRead More
Smart Nursing BraRead More